Literature DB >> 16432831

Clinicopathological characteristics of colorectal cancers with loss of imprinting of insulin-like growth factor 2.

Jun-ichi Sasaki1, Fumio Konishi, Yutaka J Kawamura, Toshihiro Kai, Osamu Takata, Toshihiko Tsukamoto.   

Abstract

Loss of imprinting (LOI), the biallelic expression of an imprinting gene, of insulin-like growth factor 2 (IGF2) has been reported to be associated with colorectal carcinogenesis because of its high prevalence in normal colorectal mucosa as well as cancerous tissue in patients with colorectal cancer. However, the characteristics of colorectal cancer associated with IGF2 LOI have not been clearly demonstrated. In this study, we investigated the IGF2 LOI status of tumor and normal mucosa in 255 consecutive patients with colorectal cancer. Of these, 95 were informative for IGF2 LOI, by direct sequencing of mRNA of IGF2. Regarding the LOI status in each patient, the prevalence of LOI in nontumorus normal mucosa was significantly higher in cases with LOI-positive cancer than in those with LOI-negative cancer (p < 0.001). Concerning the clinicopathological characteristics of LOI-positive cancer, the prevalence of poorly differentiated or mucinous carcinoma (p = 0.016) and of right-sided locations (p = 0.009) were significantly higher than those of LOI-negative cancer. Contrary to past reports that revealed a significant correlation between microsatellite instability (MSI) and IGF2 LOI in a relatively small series of noncohort patients, our study did not find a statistically significant difference in LOI-positive rate between MSI-positive and -negative cases. Our results suggested the presence of a particular type of colorectal cancer associated with the proximal colon and poor differentiation, but independent of MSI. These results may contribute to clarification of the mechanism of colorectal tumorigenesis and to determining an appropriate screening strategy for colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16432831     DOI: 10.1002/ijc.21741

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  Genetic variation in insulin pathway genes and distal colorectal adenoma risk.

Authors:  A Joan Levine; Ugonna Ihenacho; Won Lee; Jane C Figueiredo; David J Vandenberg; Christopher K Edlund; Brian D Davis; Mariana C Stern; Robert W Haile
Journal:  Int J Colorectal Dis       Date:  2012-05-30       Impact factor: 2.571

2.  Heredity and DNA methylation in colorectal cancer.

Authors:  J R Jass
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

3.  New insights into the molecular pathogenesis of colorectal cancer.

Authors:  Kenneth E Hung; Daniel C Chung
Journal:  Drug Discov Today Dis Mech       Date:  2006

4.  Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis.

Authors:  Yoshifumi Baba; Katsuhiko Nosho; Kaori Shima; Curtis Huttenhower; Noriko Tanaka; Aditi Hazra; Edward L Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  Gastroenterology       Date:  2010-08-02       Impact factor: 22.682

5.  Carcinoma of the colon and rectum with deregulation of insulin-like growth factor 2 signaling: clinical and molecular implications.

Authors:  Djeda Belharazem; Julia Magdeburg; Ann-Kristin Berton; Li Beissbarth; Christian Sauer; Carsten Sticht; Alexander Marx; Ralf Hofheinz; Stefan Post; Peter Kienle; Philipp Ströbel
Journal:  J Gastroenterol       Date:  2016-03-17       Impact factor: 7.527

6.  Dietary factors, genetic and epigenetic influences in colorectal cancer.

Authors:  M L Pellegrini; P Argibay; D E Gomez
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

7.  Loss of imprinting and marked gene elevation are 2 forms of aberrant IGF2 expression in colorectal cancer.

Authors:  Yu-Wei Cheng; Kamran Idrees; Richard Shattock; Sajid A Khan; Zhaoshi Zeng; Cameron W Brennan; Philip Paty; Francis Barany
Journal:  Int J Cancer       Date:  2010-08-01       Impact factor: 7.396

8.  Loss of imprinting of IGF2 and the epigenetic progenitor model of cancer.

Authors:  Mark B Leick; Christopher J Shoff; Erwin C Wang; Jaclyn L Congress; G Ian Gallicano
Journal:  Am J Stem Cells       Date:  2011-08-19

9.  Temporal stability and age-related prevalence of loss of imprinting of the insulin-like growth factor-2 gene.

Authors:  Marcia Cruz-Correa; Ronghua Zhao; Myriam Oviedo; Raul D Bernabe; Mercedes Lacourt; Alberto Cardona; Reynold Lopez-Enriquez; Steven Wexner; Carmen Cuffari; Linda Hylind; Elizabeth Platz; Hengmi Cui; Andrew P Feinberg; Francis M Giardiello
Journal:  Epigenetics       Date:  2009-02-27       Impact factor: 4.528

10.  Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of lymph node metastasis and gastric corpus cancer.

Authors:  Yang Lu; Ping Lu; Zhi Zhu; Huimian Xu; Xike Zhu
Journal:  J Exp Clin Cancer Res       Date:  2009-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.